Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 6, 2015, Pages 741-752

  Hourigan, S K ^a,b   Chen, L A ^a,c   Grigoryan, Z ^c   Laroche, G ^a   Weidner, M ^a   Sears, C L ^a   Oliva Hemker, M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Virginia Cancer Specialists   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; COLESTYRAMINE; CORTICOSTEROID; FLUDROCORTISONE; INFLIXIMAB; LOPERAMIDE; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; RNA 16S;

16S RRNA GENE; ADOLESCENT; ADULT; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GENE; CHILD; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM DIFFICILE TOXIN B GENE; COLONOSCOPY; CONTROLLED STUDY; FECES MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; FEMALE; GENE SEQUENCE; HUMAN; INFLAMMATORY BOWEL DISEASE; MALE; MICROBIAL DIVERSITY; MICROBIOME; NONHUMAN; OUTCOME ASSESSMENT; PEPTOCLOSTRIDIUM DIFFICILE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT INFECTION; SCHOOL CHILD; SPECIES COMPOSITION; SPECIES RICHNESS; SYMPTOM; THERAPY EFFECT; TRANSPLANTATION; CLOSTRIDIUM INFECTIONS; COMPLICATION; FECAL MICROBIOTA TRANSPLANTATION; FECES; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; RECURRENT DISEASE;

ADOLESCENT; CHILD; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLONOSCOPY; FECAL MICROBIOTA TRANSPLANTATION; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MICROBIOTA; POLYMERASE CHAIN REACTION; RECURRENCE; RNA, RIBOSOMAL, 16S;

EID: 84939562792     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13326     Document Type: Article

References (56)

1. Ananthakrishnan AN,. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8: 17-26.
2. Sammons JS, Toltzis P,. Recent trends in the epidemiology and treatment of C. difficile infection in children. Curr Opin Pediatr 2013; 25: 116-21.
3. Goodhand JR, Alazawi W, Rampton DS,. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 428-41.
4. Rodemann JF, Dubberke ER, Reske KA, et al,. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-44.
5. Martinelli M, Strisciuglio C, Veres G, et al,. Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN Study. Inflamm Bowel Dis 2014; 20: 2219-25.
6. McFarland LV, Elmer GW, Surawicz CM,. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-75.
7. Barbut F, Richard A, Hamadi K, et al,. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38: 2386-8.
8. van Nood E, Vrieze A, Nieuwdorp M, et al,. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 36: 407-15.
9. Cammarota G, Masucci L, Ianiro G, et al,. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41: 835-43.
10. Song Y, Garg S, Girotra M, et al,. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS ONE 2013; 8: e81330.
11. Shankar V, Hamilton MJ, Khoruts A, et al,. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome 2014; 2: 13.
12. Seekatz AM, Aas J, Gessert CE, et al,. Recovery of the gut microbiome following fecal microbiota transplantation. MBio 2014; 5: e00893-14.
13. Russell GH, Kaplan JL, Youngster I, et al,. Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 58: 588-92.
14. Pierog A, Mencin A, Reilly NR,. Fecal microbiota transplantation in children with recurrent Clostridium difficile infection. Pediatr Infect Dis J 2014; 33: 1198-200.
15. Kronman MP, Nielson HJ, Adler AL, et al,. Fecal microbiota transplantation via nasogastric tube for recurrent C. difficile infection in pediatric patients. J Pediatr Gastroenterol Nutr 2015; 60: 23-6.
16. Houghteling PD, Walker WA,. Why is initial bacterial colonization of the intestine important to the infant's and child's health? J Pediatr Gastroenterol Nutr 2015; 60: 294-307.
17. Manichanh C, Borruel N, Casellas F, et al,. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9: 599-608.
18. Gevers D, Kugathasan S, Denson LA, et al,. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014; 15: 382-92.
19. Hourigan SK, Oliva-Hemker M, Hutfless S,. The prevalence of Clostridium difficile infection in pediatric and adult patients with inflammatory bowel disease. Dig Dis Sci 2014; 59: 2222-7.
20. Bakken J, Borody T, Brandt L, et al,. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-9.
21. Caporaso JG, Lauber CL, Walters WA, et al,. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J 2012; 6: 1621-4.
22. Aronesty E,. Comparison of sequencing utility programs. Open Bioinformatics 2013; 7: 1-8.
23. Caporaso JG, Kuczynski J, Stombaugh J, et al,. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7: 335-6.
24. McDonald D, Price MN, Goodrich J, et al,. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J 2012; 6: 610-8.
25. Vazquez-Baeza Y, Pirrung M, Gonzalez A, et al,. Gigascience 2013; 2: 16.
26. Segata N, Izard J, Waldron L, et al,. Metagenomic biomarker discovery and explanation. Genome Biol 2011; 12: R60.
27. Stamper PD, Alcabasa R, Aird D, et al,. Comparison of a commercial realtime PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol 2009; 47: 373-8.
28. Hourigan SK, Chirumamilla SR, Ross T, et al,. Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2744-52.
29. Knights D, Silverberg MS, Weersma RK, et al,. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Me 2014; 6: 107.
30. Kelly CR, Ihunnah C, Fischer M, et al,. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109: 1065-71.
31. Papa E, Docktor M, Smillie C, et al,. Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS ONE 2012; 7: e39242.
32. Dutta SK, Girotra M, Garg S, et al,. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2014; 12: 1572-6.
33. Walia R, Garg S, Song Y, et al,. Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome. J Pediatr Gastroenterol Nutr 2014; 59: 565-70.
34. De Leon LM, Watson JB, Kelly CR,. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11: 1036-8.
35. Quera R, Espinoza R, Estay C, et al,. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. J Crohns Colitis 2014; 8: 252-3.
36. Alang N, Kelly C,. Weight gain after fecal microbiota transplantation. OFID 2015; 2: ofv004. Online ISSN 2328-8957.
37. Brecher SM, Novak-Weekley SM, Nagy E,. Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon. Clin Infect Dis 2013; 57: 1175-81.
38. Lawley TD, Clare S, Walker AW, et al,. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012; 8: e1002995.
39. Skraban J, Dzeroski S, Zenko B, et al,. Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes. PLoS ONE 2013; 8: e58005.
40. Shahinas D, Silverman M, Sittler T, et al,. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio 2012; 3: e00338-12.
41. Antharam VC, Li EC, Ishmael A, et al,. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 2013; 51: 2884-92.
42. Grehan MJ, Borody TJ, Leis SM, et al,. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010; 44: 551-61.
43. Hamilton MJ, Weingarden AR, Unno T, et al,. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2013; 4: 125-35.
44. Frank DN, St Amand AL, Feldman RA, et al,. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-5.
45. Strauss J, Kaplan GG, Beck PL, et al,. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 2011; 17: 1971-8.
46. Castellarin M, Warren RL, Freeman JD, et al,. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22: 299-306.
47. Kostic AD, Chun E, Robertson L, et al,. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14: 207-15.
48. Rubinstein MR, Wang X, Liu W, et al,. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 2013; 14: 195-206.
49. Kelsen JR, Kim J, Latta D, et al,. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 50-5.
50. Chang JY, Antonopoulos DA, Kalra A, et al,. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 1: 435-8.
51. Brandt LJ, Aroniadis OC, Mellow M, et al,. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079-87.
52. Suskind DL, Singh N, Nielson H, et al,. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2015; 60: 27-9.
53. Kump PK, Gröchenig HP, Lackner S, et al,. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013; 19: 2155-65.
54. Drossman DA,. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
55. Spiller RC,. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124: 1662-71.
56. Piche T, Vanbiervliet G, Pipau FG, et al,. Low risk of irritable bowel syndrome after Clostridium difficile infection. Can J Gastroenterol 2007; 21: 727-31.